Literature DB >> 7935698

Risks of salmeterol?

F N Finkelstein.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7935698     DOI： 10.1056/nejm199411103311916

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  8 in total

Review 1.  Salmeterol. A review of its pharmacological properties and clinical efficacy in the management of children with asthma.

Authors:  J C Adkins; D McTavish
Journal:  Drugs       Date:  1997-08       Impact factor: 9.546

Review 2.  Asthma treatment in the 21st century: what's next?

Authors:  Stephen P Peters
Journal:  Clin Rev Allergy Immunol       Date:  2004-12       Impact factor: 8.667

3.  Case-control study of salmeterol and near-fatal attacks of asthma.

Authors:  C Williams; L Crossland; J Finnerty; J Crane; S Holgate; N Pearce; R Beasley
Journal:  Thorax       Date:  1998-01       Impact factor: 9.139

4.  Drug use and pulmonary death rates in increasingly symptomatic asthma patients in the UK.

Authors:  C R Meier; H Jick
Journal:  Thorax       Date:  1997-07       Impact factor: 9.139

Review 5.  Salmeterol. An appraisal of its quality-of-life benefits and potential pharmacoeconomic positioning in asthma.

Authors:  D H Peters; D Faulds
Journal:  Pharmacoeconomics       Date:  1995-06       Impact factor: 4.981

Review 6.  Nocturnal asthma uncontrolled by inhaled corticosteroids: theophylline or long-acting beta2 agonists?

Authors:  T D Holimon; C C Chafin; T H Self
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 7.  Airway subsensitivity with long-acting beta 2-agonists. Is there cause for concern?

Authors:  B J Lipworth
Journal:  Drug Saf       Date:  1997-05       Impact factor: 5.228

Review 8.  Salmeterol (Serevent) asthma trial halted early.

Authors:  Eric Wooltorton
Journal:  CMAJ       Date:  2003-03-18       Impact factor: 8.262
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.